LogicBio Therapeutics, Inc.
Lead Plaintiff Deadline: 05/18/2020
SUMMARY OF CASE:
A securities class action has been filed against LogicBio Therapeutics, Inc. (LOGC) on behalf of all purchasers of LogicBio Therapeutics common stock between December 3, 2018 through February 10, 2020. This case has been filed in the USDC – N.J.
The Complaint alleges that on February 10, 2020, post-market, LogicBio issued a press release announcing “the U.S. Food and Drug Administration (FDA) has placed a clinical hold on [LogicBio’s] Investigational New Drug (IND) submission for LB-001 for the treatment of methylmalonic acidemia (MMA) pending the resolution of certain clinical and nonclinical questions.”
On this news, LogicBio’s share price fell sharply during intraday trading on February 11, 2020, on unusually high trading volume.